MINDMAZE
11.7.2022 15:02:07 CEST | Business Wire | Press release
MindMaze, a global pioneer in the development of neurotechnology, today confirms a new partnership with Alfa Romeo F1 Team ORLEN. Through this partnership, MindMaze will expand its groundbreaking research using its MindDrive brain technology platform to bring together advanced neuroscience, state-of-the-art technology, and engineering to boost safety and human performance in motorsport.
“We are delighted to be working closely with the Alfa Romeo F1 team to expand our partnership. Human performance is tested to the maximum in F1, which is why the research we are conducting with team ORLEN is so important. Our goal is not only to generate and study data that benefit human performance in motorsport, but also to inform the future of innovation for universal safety features across the entire automotive industry,” says MindMaze CEO Tej Tadi.
MindDrive’s brain technology platform is part of the company’s R&D innovation division— MindMaze Labs. The collaboration will include holistic research assessing both car and driver. The brain technology platform will specifically monitor human performance by capturing brain data, both on and off the racetrack. MindMaze’s F1 partnership represents a novel new field of study that underscores the company’s objective to transform brain health by decoding the brain and harnessing its ability to accelerate recovery from injury, learn, and adapt.
Frédéric Vasseur, Team Principal of Alfa Romeo F1 Team ORLEN, added, “Innovation is at the heart of everything we do in Formula One, so I’m proud to welcome MindMaze as a neurotechnology pioneer to our partner family. It is a company that has shown its research has real-world benefits, and I’m looking forward to combining our deep technical competencies to see what insights we can unlock together.”
MindMaze recently showcased the brain technology and its motorsport research at the Miami Grand Prix, where MindMaze was a founding partner. As part of the agreement, MindMaze will have brand sponsorship on the safety helmets of Alfa Romeo F1 Team ORLEN drivers Valtteri Bottas and Zhou Guanyu for the remainder of the 2022 F1 season.
MindMaze’s F1 programme is part of its growing portfolio of research in motorsport. Currently, it has a MindDrive-focused research project underway in the US with the Andretti Autosport Indycar team and its brain health ambassador, Romain Grosjean. Previous partners include F1’s McLaren and Haas teams.
About MindMaze
Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutics solutions for brain health and recovery. Its mission is to accelerate the brain’s ability to recover, learn, and adapt. The company has two core divisions— Healthcare and Labs— working collaboratively at the intersection of neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence. MindMaze Healthcare is advancing a universal platform for brain health with breakthrough solutions to some of the world’s most challenging problems in neurology, including stroke, Parkinson’s disease, and Alzheimer’s disease. MindMaze Labs, the company’s R&D innovation hub, is focused on the future of human computing— working across multiple industries to innovate and build the next generation of human-machine interfaces. The company has offices in Lausanne, Baltimore, London, Paris, and Mumbai. For more information, please visit www.mindmaze.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005379/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2026 Results3.11.2026 22:30:00 CET | Press release
Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026Raising Low-End of Full Year 2026 Financial Guidance RangesRecently Completed $500M Share Repurchase AuthorizationFood Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027 IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modes
2026–2027 World Branding Awards Honours Global “Brand of the Year” Winners at Hampton Court Palace3.11.2026 21:00:00 CET | Press release
The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release
Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release
Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom